enGene Holdings Inc. (ENGN) Financial Analysis & Valuation | Quarter Chart
enGene Holdings Inc. (ENGN)
ENGNPrice: $7.07
Fair Value: 🔒
🔒score
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral... more
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnolog... more
Description
Shares
| Market Cap | $361.95M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CA | CEO | Ronald H. W. Cooper |
| IPO Date | 2022-02-01 | CAGR | — |
| Employees | 56 | Website | www.engene.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ENGN chart loading...
Fundamentals
Technicals
| Enterprise Value | $615.51M | P/E Ratio | -3.14 |
| Forward P/E | -4.09 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 2.03 |
| P/CF Ratio | -5.59 | P/FCF Ratio | -4.22 |
| EPS | $-2.25 | EPS Growth 1Y | -76.32% |
| EPS Growth 3Y | -77.22% | EPS Growth 5Y | — |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.05% | ROA | -0.03% |
| ROCE | 0.16% | Current Ratio | 11.75 |
| Quick Ratio | 11.75 | Cash Ratio | 1.49 |
| Debt/Equity | 0.03 | Interest Coverage | 16.4 |
| Altman Z Score | 2.62 | Piotroski Score | 1 |